Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Drew Moghanaki

Thoracic Rad Onc · UCLA

View

Dr. Himanshu Nagar

GU Rad Onc · MSK

View

Dr. Michael Dykstra

General Rad Onc · UM

View

Dr. Lori Pierce

Breast Rad Onc · UM

View

Dr. William Hwang

GI Rad Onc · MGH

View

Dr. Kamran Ahmed

Breast Rad Onc · Moffitt Cancer Center

View

Dr. James Janopaul-Naylor

GU Rad Onc · MSK

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.

    Sep 27, 2023DOI: 10.1245/s10434-023-14350-1Journal ArticleASO

    Written by: Caressa HuiAgnes EwongwoBrianna LauGeorge FisherDaniel DelittoGeorge PoultsidesQuoc-Anh HoElham RahimyErqi PollomDaniel T ChangLucas K Vitzthum

    Find these authors on Roon

    ER
    Dr. Elham Rahimy
    CNS Rad Onc · Stanford

    Summary

    BACKGROUND: Improved treatment strategies are needed for patients with locally advanced gastric cancer with poor response to neoadjuvant chemotherapy. We aimed to describe patterns of failure for patients with no or partial response (NR, PR) to preoperative chemotherapy.PATIENTS AND METHODS: We analyzed patients with locally advanced gastric cancer treated from 2008 to 2022 with preoperative chemotherapy followed by surgery with D2 resection. We excluded patients who received radiation. Cumulative incidence of locoregional failure (LRF) and distant metastases (DM) were calculated. For patients with recurrent abdominal disease, hypothetical radiation clinical treatment volumes (CTV) were contoured on postoperative scans and compared with patterns of recurrence.RESULTS: A total of 60 patients were identified. The most used preoperative chemotherapy was FLOT (38.6%), followed by FOLFOX (30%) and ECF/ECX/EOX (23.3%). Four (6.7%), 40 (66.7%), and 9 patients (15%) had a complete pathologic response (CR), PR, and NR to neoadjuvant therapy, respectively. Among patients without a CR, 3-year overall and progression-free survival rates were 62.3% (95% CI 48-76.6%) and 51.3% (95% CI 36.9-65.7%), respectively. Three-year cumulative incidence of LRF and DM were 8.4% (95% CI 0.4-16.4%) and 41.0% (95% CI 26.3-55.4%), respectively. Absolute rates of patients having the first site of recurrence encompassed by a postoperative radiation CTV was 2.0% for patients without a CR and 0% for patients with NR.CONCLUSIONS: Patients with locally advanced gastric cancer with less than a CR to chemotherapy have poor outcomes due to high rates of DM. Adjuvant locoregional therapy such as radiation is unlikely to affect survival.
    ERDr. Elham Rahimy

    Dr. Elham Rahimy

    Radiation Oncology · Central Nervous System Cancer Radiation Oncology
    Stanford Medicine
    elham